


Virologists publish new findings on SARS-CoV-2 treatment option

July 2 2021



Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

A recent study by Kansas State University virologists demonstrates successful postinfection treatment for SARS-CoV-2, the virus that causes COVID-19.



College of Veterinary Medicine researchers Yunjeong Kim and Kyeong-Ok "KC" Chang published the study in the journal *Proceedings of the National Academy of Sciences*. They found that animal models infected with SARS-CoV-2 and treated with a deuterated protease inhibitor had significantly increased survival and decreased lung <u>viral load</u>.

The results suggest that postinfection treatment with inhibitors of proteases that are essential for viral replication may be an <u>effective</u> <u>treatment</u> against SARS-CoV-2. These <u>protease inhibitors</u> are a class of antiviral drugs that prevent viral replication by selectively binding to viral proteases and blocking the activation of proteins that are necessary for the production of infectious viral particles.

"We developed the protease inhibitor GC376 for treating a fatal coronavirus infection in cats, which is now under commercial development as an investigational new animal drug," said Kim, associate professor of diagnostic medicine and pathobiology. "After COVID-19 emerged, many research groups reported that this inhibitor is also effective against the coronavirus that causes COVID-19, and many are currently pursuing the development of protease inhibitors as a treatment."





Kansas State University researchers Kyeong-Ok "KC" Chang, left, and Yunjeong Kim have published a new study about a successful postinfection for SARS-CoV-2, the virus that causes COVID-19. Credit: Kansas State University

Kim and Chang modified GC376 using a tool called deuteration to test



its efficacy against SARS-CoV-2.

"Treating SARS-CoV-2-infected mice with deuterated GC376 significantly improved survival, <u>viral replication</u> in lungs and weight losses, which shows the efficacy of the antiviral compound," said Chang, professor of diagnostic medicine and pathobiology. "The results suggest deuterated GC376 has a potential for further development, and this deuteration method can be utilized to other antiviral compounds to generate potent inhibitors."

The virologists are continuing to develop improved inhibitors using various methods. Deuterated GC376 is currently being evaluated for further potential development.

More information: Chamandi S. Dampalla et al, Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection, *Proceedings of the National Academy of Sciences* (2021). DOI: 10.1073/pnas.2101555118

Provided by Kansas State University

Citation: Virologists publish new findings on SARS-CoV-2 treatment option (2021, July 2) retrieved 5 May 2024 from <u>https://medicalxpress.com/news/2021-07-virologists-publish-sars-cov-treatment-option.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.